(CIDRAP News) A spokesman for Panasonic Corp. said today that the company had no proprietary information about any increased risk of an influenza pandemic in December 2008 when it instructed some of its overseas employees to send their families back to Japan by September.
(CIDRAP News) News reports that Panasonic Corp. has asked some of its overseas employees to send their families home to Japan because of the threat of pandemic influenza fueled puzzlement and speculation today about the global H5N1 risk and whether other companies might follow suit.
(CIDRAP News) A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culturea combination of techniques that entails some risk but may boost immune response and shorten production time.
(CIDRAP News) A World Health Organization (WHO) working group will meet in Geneva over the next 4 days to try to solve an impasse over how countries share their H5N1 avian influenza virus samples, a disagreement that pits developing countries' demand for affordable vaccines against the global need to monitor virus changes and develop pandemic vaccines.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Indonesian officials said today they have sent a sample from a recent victim of H5N1 influenza to the World Health Organization (WHO), apparently ending the country's prolonged withholding of H5N1 samples.
(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.